{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cabaletta Bio, Inc."},"Symbol":{"label":"Symbol","value":"CABA"},"Address":{"label":"Address","value":"2929 ARCH STREET,SUITE 600, PHILADELPHIA, Pennsylvania, 19104, United States"},"Phone":{"label":"Phone","value":"+1 267 759-3100"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers."},"CompanyUrl":{"label":"Company Url","value":"https://www.cabalettabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David J. Chang","title":"Chief Medical Officer"},{"name":"Gwendolyn Binder-Scholl","title":"President-Science & Technology"},{"name":"Samik Basu","title":"Chief Scientific Officer"},{"name":"Steven Nichtberger","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}